Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

2014; Elsevier BV; Volume: 123; Issue: 15 Linguagem: Inglês

10.1182/blood-2013-09-527226

ISSN

1528-0020

Autores

David H. McDermott, Qian Liu, Daniel Velez, Lizbeeth Lopez, Sandra Anaya‐O’Brien, Jean Ulrick, Nana Kwatemaa, Judy Starling, Thomas A. Fleisher, Debra A. Long Priel, Melissa A. Merideth, Robert Giuntoli, Moses O. Evbuomwan, Patricia Littel, Martha Marquesen, Dianne Hilligoss, Rosamma DeCastro, George Grimes, Samuel Hwang, Stefania Pittaluga, Katherine R. Calvo, Pamela Stratton, Edward W. Cowen, Douglas B. Kuhns, Harry L. Malech, Philip M. Murphy,

Tópico(s)

Immunotherapy and Immune Responses

Resumo

Key Points Plerixafor can be given safely to WHIM syndrome patients twice daily for a 6-month period and appears promising as a treatment.

Referência(s)